来源：新浪财经 日前，日播时尚通过发行股份及支付现金的方式，收购四川茵地乐材料科技集团有限公司71%股权事项 获得证监会同意注册的批复。 茵地乐是国内锂电池粘结剂行业的"隐形冠军"，在锂电池PAA类粘结剂市场中占有率高达49%。茵地乐 的客户包括比亚迪、中创新航、蜂巢能源、宁德时代等行业头部企业。 值得注意的是，这项交易得到了实控人梁丰的推动。梁丰不仅是日播时尚的实际控制人，同时也是另一 家上市公司璞泰来的创始人和实控人，该公司主营业务为锂离子电池关键材料及自动化工艺设备。 评估报告显示，以2024年12月31日为评估基准日，茵地乐股东全部权益评估值为20.05亿元，较净资产 账面价值增值10.19亿元，增值率高达103.40%。 日播时尚近年来主营业务表现疲软。2024年公司实现营业收入8.66亿元，同比下滑15.68%；归母净利润 亏损1.59亿元，一举吞噬过往三年累计归母净利润。 茵地乐的业绩表现相当亮眼。2023年、2024年及2025年1-5月分别实现净利润1.81亿元、2.04亿元及1.30 亿元，毛利率分别达到52.42%、51.71%及55.72%。 不过，根据交易方做出的业绩承诺，茵地乐20 ...

长江商报消息 通过高溢价收购，通业科技（300960.SZ）将业务延伸至电力物联网芯片领域。 12月27日晚间，通业科技披露资产收购计划，拟以5.61亿元现金购买北京思凌科半导体技术有限公司 （以下简称"思凌科"）91.69%股权。本次交易完成后，思凌科将成为上市公司的控股子公司。 资料显示，思凌科聚焦于电力物联网通信芯片领域。通过本次收购，通业科技将在原有轨道交通机车车 辆电气业务的基础上延伸市场，提升核心竞争力。 长江商报记者注意到，本次交易中，思凌科整体估值溢价率达387.41%。交易完成之后，通业科技将新 增商誉3.59亿元。 溢价收购的同时，交易对手方作出思凌科未来三年净利润不低于1.75亿元的业绩承诺，且为了加强核心 团队成员与公司绑定，通业科技的实控方还拟作价1.88亿元向思凌科实控人控制的共青城思凌企管投资 合伙企业（有限合伙）（以下简称"思凌企管"）转让6%上市公司股份。 截至2025年7月末，通业科技账面现金及现金等价物余额2亿元，与本次交易总支付对价5.61亿元存在一 定资金缺口。据测算，交易完成之后，通业科技资产负债率将从37.53%上升至66.95%，其面临的财务 与整合风险不容忽视 ...

公告显示，公司已与科凯电子实际控制人王建绘、王建纲等补偿方签署补充协议，取消原90%的业绩补 偿触发比例，改为当科凯电子2026年、2027年实际净利润低于当年承诺净利润时，补偿方即触发补偿义 务。补偿方优先以本次交易中取得的上市公司股份补偿，不足部分以现金补足，累计补偿金额不超过其 取得的总对价9.07亿元，占交易总对价的69.07%。 补偿方承诺，科凯电子2025年至2028年累计承诺净利润不低于5.16亿元，略高于收益法评估预测的5.14 亿元。作为核心补偿措施，补偿方还承诺对科凯电子2028年末应收账款余额的80%回收率进行兜底，未 达部分将承担垫付义务。 评估方法与商誉风险 广州思林杰科技股份有限公司（以下简称"思林杰"）近日发布公告，就发行股份及支付现金购买青岛科 凯电子研究所股份有限公司（以下简称"科凯电子"）71%股权并募集配套资金事项，对上海证券交易所 问询函相关问题进行回复。公告披露了交易方案调整、业绩补偿机制优化、标的资产估值合理性及商誉 风险等关键信息。 交易方案与支付安排 根据公告，本次交易总对价为13.14亿元，其中以股份支付5.91亿元，向标的公司实际控制人支付现金9 亿元。现金 ...

出品：新浪财经上市公司研究院 作者：新消费主张/cici 12月11日，国内母婴零售龙头企业孩子王儿童用品股份有限公司（以下简称"孩子王"）向港交所递交招 股书寻求"A+H"两地上市，独家保荐人为华泰国际。 母婴童业务增长已呈现明显疲态。2023年、2024年及2025年前三季度，该业务营收同比增幅持续徘徊在 个位数区间。纵使乐友在2023年8月纳入并表范围，依旧未给孩子王营收层面带来较大起色。此外，孩 子王全年店均收入及门店坪效已连续下滑。2023年，孩子王店均收入同比下降10.79%，坪效同比下降 9.14%；2024年在此基础上进一步下降，孩子王直营店均收入同比下降4.31%，门店坪效同比下降 3.17%。 2025年上半年，乐友国际仅实现净利润3369.88万元，不到全年目标（1.18亿元）的三分之一，下半年业 绩压力巨大。除此之外，乐友2025年上半年店均收入、坪效均出现下滑，其中店均收入为133.81万元， 同比下降5.45%；门店坪效为5241.61元/平方米，同比下降9.69%。 母婴童业务增长乏力：低毛利品类收入占比高 全年坪效、店均收入持续下滑 孩子王创立于2009年，主要从事中高端品牌母 ...

祥源文旅（维权）近日发布公告，全资子公司拟以自有资金3.45亿元收购金秀莲花山景区开发有限公司 100%股权。 评估报告显示，金秀莲花山的评估增值率高达241.19%，而公司商誉余额已攀升至8.46亿元。这仅仅是 祥源文旅一系列并购中的最新一例。 频繁并购 金秀莲花山2024年营收429.54万元、净利润168.92万元。评估机构预测其2026年营收将达7015.9万元， 净利润1650.36万元。这意味着公司需要在两年内实现营收增长超过15倍的目标。 祥源文旅的前身是万家文化，曾于2017年卷入赵薇夫妇主导的龙薇传媒空壳收购案。同一年，祥源控股 以16.74亿元收购万家集团100%股权，间接持有万家文化29.72%股权，实控人变更为俞发祥。 此后，上市公司更名并开启系列资产重组。2022年，公司以16.32亿元对价购入实控人旗下多项文旅资 产。 2023年8月，公司完成雅安祥源碧峰峡旅游有限公司收购，同时置入了酒店、茶业等资产，并将无线增 值业务等业务及资产进行了置出。 2025年10月17日，海昌海洋公园控股有限公司（02255.HK）发布公告宣布，祥源控股注资22.95亿港 元、以持股38.60%正式成 ...

标的公司则面临"大客户依赖症"。兴中科技全资子公司五新科技前五大客户销售额占比约80%。 本次并购后，上市公司将面临多重新增风险，其中最为突出的是商誉减值风险。 本次交易完成后，上市公司合并报表层面新增商誉33，947.99 万元，若未来标的公司经营状况未达预 期，可能需计提商誉减值准备，直接影响公司净利润。 12月6日，五新隧装发布关于重大资产重组事项的进展公告，公司拟通过发行股份及支付现金方式购买 湖南中铁五新重工有限公司100%股权和怀化市兴中科技股份有限公司99.9057%股权并募集配套资金暨 关联交易事项，总对价约26.49亿元。 这起交易作为北交所"并购六条"新规后首单获通过的发股购买资产项目，被视为北交所深化并购改革的 标志性事件。 五新隧装此次交易方案经历多次调整。最新方案显示，五新隧装将收购兴中科技99.9057%股权及五新 重工100%股权。根据交易方案，本次交易总对价为264，859.03万元。新隧装计划通过发行股份及支付 现金方式完成收购，其中股份支付约22.78亿元，现金支付约3.71亿元。 本次交易中两家标的公司的评估增值率差异显著，引发了市场关注。评估基准日为2024年11月30 ...

Core Viewpoint - The acquisition of a 41% stake in Shaanxi Ruisheng Biotechnology Co., Ltd. by Shanghai Haili Biotechnology Co., Ltd. is primarily a means to offset a transaction price difference due to declining performance of Ruisheng Biotech, which has been impacted by increased competition and policy changes [2][3][4]. Group 1: Acquisition Details - On November 30, Haili Biotech signed an agreement to acquire a 41% stake in Ruisheng Biotech from Meilun Management Co., Ltd. [2] - The original acquisition of 55% of Ruisheng Biotech was completed in October 2024 for 935 million yuan, with performance guarantees set for the following years [3]. - Due to a decline in Ruisheng's performance starting in Q2 2024, Haili Biotech adjusted the valuation of the acquisition, reducing the price from 935 million yuan to 535.7 million yuan, resulting in a price difference of approximately 399.3 million yuan that Meilun was unable to pay in cash [3][4]. Group 2: Financial Performance - Ruisheng Biotech's revenue for 2024 and the first nine months of 2025 was 265 million yuan and 105 million yuan, respectively, with net profits of 139 million yuan and 43.06 million yuan [5]. - The valuation of Ruisheng Biotech was adjusted to 974 million yuan, reflecting a significant increase from its book value of 301 million yuan, resulting in a valuation increase of 673 million yuan, or 223.21% [6]. - Haili Biotech's revenue for 2024 was 271 million yuan, a 12.59% increase year-on-year, with a net profit of 171 million yuan, representing a 172.28% increase [7]. Group 3: Market Challenges - Haili Biotech's main businesses, including in vitro diagnostic reagents and oral tissue repair materials, are facing pressures due to intensified market competition and declining product prices [8]. - In Q3 2025, Haili Biotech experienced a significant revenue decline of 40.2% year-on-year, with total revenue of 150 million yuan, a 14.15% decrease compared to the previous year [8].

Core Viewpoint - Tianyi Ma is pursuing a strategic acquisition of 98.5632% of Guangdong Xingyun Kaiwu Technology Co., Ltd. to address ongoing operational pressures and declining profits since its IPO in 2021 [2][5]. Group 1: Acquisition Details - The acquisition involves a total valuation of 1.21 billion yuan for 100% of Xingyun Kaiwu, representing a premium of over 6 times its net asset value [2][3]. - The transaction structure includes a combination of cash and stock payments, with 50.2672% of the shares purchased in cash and 48.2960% through stock issuance [3]. - The acquisition is expected to add approximately 1.049 billion yuan in goodwill to Tianyi Ma's balance sheet, which constitutes 78% of the company's net assets [2][9]. Group 2: Financial Performance and Projections - Tianyi Ma's net profits have declined for three consecutive years, with projected losses of 49.55 million yuan in 2024 [5]. - Xingyun Kaiwu is projected to achieve net profits of no less than 90 million yuan, 95 million yuan, and 105 million yuan for the years 2025 to 2027, totaling at least 290 million yuan [4]. - Post-acquisition, Tianyi Ma's revenue is expected to increase significantly, with projections showing a rise from 146 million yuan to 394 million yuan in the first half of 2025, marking a 170% increase [8]. Group 3: Strategic Rationale - The acquisition is part of Tianyi Ma's broader strategy to transform and enhance its business model, focusing on capital operations and optimizing its industry layout [7]. - The merger aims to create a comprehensive industry layout from government information systems to consumer IoT, leveraging both companies' strengths in technology [8]. - Xingyun Kaiwu's strong technical capabilities and extensive patent portfolio (217 patents and 199 software copyrights) are expected to complement Tianyi Ma's existing offerings [7].

Group 1 - The independent director of Aopumai, Tao Hua'an, opposed the company's acquisition of 1.45 billion yuan, stating that the company does not currently have a necessity for mergers and acquisitions [1][2] - This marks the fourth time Tao has voted against acquisition-related proposals during board meetings [1] - Aopumai plans to acquire control of Pengli Biotechnology, which specializes in preclinical CRO services, with a final transaction price of approximately 1.45 billion yuan, reflecting a valuation increase of 56.62% [1] Group 2 - Post-acquisition, Aopumai expects to add 555 million yuan in goodwill, which would account for 849.41% of the projected net profit for 2024 [2] - The CRO industry is characterized by intense competition and significant market segmentation, with risks of price wars and regulatory impacts [2] - Aopumai reported revenue of approximately 272 million yuan for the first three quarters of the year, representing a year-on-year growth of 25.79%, and a net profit of about 49.43 million yuan, up 81.48% year-on-year [2]

Core Viewpoint - Aier Eye Hospital, once regarded as a leader in ophthalmology, is currently facing a dual crisis of trust and operational challenges since its IPO, highlighted by allegations of financial misconduct and stagnant growth [1] Group 1: Charity Fund Flow and Allegations - Aier Eye Hospital has been accused of a "donate and recoup" model, where over 55 million yuan was paid to a charity fund, which subsequently funneled money back to Aier's subsidiaries, creating a closed-loop system [2] - Beneficiaries are reportedly required to receive treatment within Aier's network, leading to concerns that charitable donations are effectively converted into corporate revenue [2] - Allegations suggest that Aier profits from insurance reimbursements, with a reported 1,300 yuan received per cataract surgery, despite actual costs being significantly lower, indicating a potential dual-track profit scheme [2] Group 2: Compliance Risks and Penalties - Multiple Aier hospitals have faced penalties for insurance fraud, raising further doubts about the company's operational integrity [3] - Specific fines include 131,500 yuan for project switching at Xiangshan Aier Hospital and 22,400 yuan for overcharging at Yangjiang Aier Hospital, among others [4] - The closed-loop operation of charity funds and insurance reimbursements may violate charity laws, transforming donations into business income and breaching regulatory boundaries [4] Group 3: Financial Performance and Stock Price Decline - Aier's revenue for the first half of 2025 reached 11.507 billion yuan, a 9.12% increase, but net profit only grew by 0.05%, marking the lowest growth rate since its IPO [5] - The second quarter saw a 12.97% year-on-year decline in net profit, indicating significant pressure on core business profitability [5] - Margins for key services have dropped, with the gross margin for refractive projects at 56.12% and optical services at 54.21%, alongside a decrease in surgery prices [5] Group 4: Goodwill and Acquisition Challenges - Aier has relied heavily on acquisitions, resulting in a goodwill of 8.722 billion yuan as of June 2025, more than doubling since 2019 [6] - Despite ongoing acquisitions, the lack of growth raises concerns about potential goodwill impairment, which could adversely affect the profit statement if acquired assets underperform [6] Conclusion - Aier Eye Hospital is confronted with unprecedented systemic risks, including issues of trust, operational integrity, and financial performance, necessitating a reevaluation of its balance between commercial interests and social responsibility [7][8]